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Purpose: To compare the effectiveness of standard revision surgery using mitomycin C (MMC) 
with revision using amniotic membrane transplantation and MMC for elevated intraocular pres-
sure (IOP) after trabeculectomy.
Patients and methods: A retrospective, nonrandomized comparative study of 36 eyes of 
36 patients with a failed trabeculectomy. Patients were divided into two groups, ie, a nonamnion-
transplanted group and an amnion-transplanted group. The amniotic membrane was placed on 
the scleral flap under the conjunctiva in the amnion-transplanted group. Both groups recovered 
filtration of aqueous humor from the surgical site with the adjunctive use of MMC. The changes 
in IOP and cumulative survival rate were compared for the two groups. Success was defined 
as a 30% reduction in IOP from the preoperative IOP and maintenance below 21 mmHg with 
or without the use of antiglaucomatous agents.
Results: The mean preoperative IOP was not significantly different in the two groups. The 
mean postoperative IOP in the nonamnion group, 12.1 ± 5.5 mmHg, was significantly lower 
than the IOP in the amnion group, 16.0 ± 3.7 mmHg. Survival curves in the two groups did not 
reach significantly different levels.
Conclusions: Conventional surgical bleb revision with MMC can significantly reduce the 
elevated IOP associated with a failed filtration bleb. The use of an amniotic membrane transplant 
did not improve the surgical outcome in our cases.
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Introduction
Trabeculectomy has been the surgery of choice in eyes with glaucoma since it 
was first described by Cairns in 1968.1 Antifibrotic drugs, such as 5-fluorouracil 
and   mitomycin C (MMC), have been commonly used adjunctively to prevent scar 
  formation, and they have increased the success rate of trabeculectomy. However, there 
is still a low but unacceptable rate of failure of trabeculectomy because of   progressive 
  scarring of the subconjunctival tissues. Patients with secondary glaucoma, aphakia, 
and prior surgery to the conjunctiva are reported to have poorer success rates   following 
trabeculectomy.2
When filtration surgery fails to reduce the intraocular pressure (IOP), a revision of 
the bleb is one of the options. Several investigators have advocated bleb revision with 
adjunctive 5-fluorouracil or MMC,3 while others have advocated the use of an amniotic 
transplant.4–7 The amniotic membrane is the innermost layer of the   three-layered fetal 
membrane, and has anti-inflammatory, antifibrotic, and antiangiogenic properties.8,9 
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pterygium excision10 and in nonhealing corneal epithelial 
defects.11 Nagai-Kusuhara et al reported that the use of an 
amniotic membrane for reconstructing a filtration bleb is 
useful for late-onset bleb leaks.12 Because of its ability to 
suppress wound healing, amniotic membrane transplanta-
tion has been used in glaucoma-filtering surgery to prevent 
subconjunctival fibrosis.4–7
The purpose of this study was to assess the effectiveness 
of conventional surgical revision using adjunctive MMC with 
that of bleb revision using adjunctive MMC and transplanta-
tion of an amniotic membrane in lowering IOP.
Material and methods
The medical charts of 36 eyes of 36 patients who had under-
gone trabeculectomy and bleb revision by a single surgeon 
(YK) at the Otemae Hospital from February 2003 to July 
2006 were reviewed. This study was approved by the Otemae 
Hospital Institutional Review Board, and the procedures 
used conformed to the tenets of the Declaration of Helsinki. 
Informed consent for the surgery had been obtained in all 
cases.
Two groups were compared; there were 24 eyes in the 
nonamnion-transplanted groups and 12 eyes in the amnion-
transplanted group. The patients in the nonamnion group had 
conventional bleb revision with adjunctive MMC between 
February 2003 and July 2005. The remaining 12 patients had 
bleb revision with amniotic membrane transplantation and 
MMC between August 2005 and July 2006.
The surgical procedures were slightly modified from 
those reported by Drolsum et al.6 For the surgery, the con-
junctiva was anesthetized with a 1 mL injection of 2% xylo-
caine, and a conjunctival incision was made approximately 
9 mm from the limbus or at the limbus. All of the cases in 
the nonamnion group had limbus-based surgery. For this, 
the conjunctiva was separated from the sclera, and the scar 
tissue was dissected from the scleral surface both anteriorly 
and posteriorly. After applying 0.4 mg/mL MMC to the sclera 
for five minutes, the surgical area was irrigated with 100 mL 
of balanced salt solution. The wall of the bleb or fibrotic 
membrane on the scleral flap was reopened as confirmed by 
the leakage of aqueous humor. The conjunctiva was closed 
with a 10-0 nylon running suture.
The amniotic membrane was obtained under sterile condi-
tions after a cesarean delivery and cryopreserved at -80°C 
in dimethyl sulfoxide until immediately before use. In the 
amnion group, a piece of amniotic membrane measuring 
approximately 7 × 10 mm was placed with the epithelial side 
over the scleral flap. Six of 12 cases (50%) in the amnion 
group had limbus-based surgery, and the remaining six 
cases had fornix-based surgery. The amniotic membrane 
was sutured to the sclera at the corneoscleral limbus using 
8-0 virgin silk. The fornix side of the amniotic membrane 
was inserted beneath the healthy conjunctiva posterior to 
the conjunctival incision line or scar line. Then two to three 
sutures were placed 5 mm from the limbus to fix the amniotic 
membrane to the sclera. The fornix end of the membrane was 
not sutured. Then the limbus-based conjunctival flap was 
closed, as was done in the nonamnionic group. The fornix-
based flap was closed by interrupted sutures at the limbus.
Postoperatively, all patients received similar topical 
medical regimen; 0.1% topical betamethasone and 0.5% 
levofloxacin for six weeks to three months which was reduced 
within three months, depending on the degree of inflamma-
tion. Patients were examined monthly for the first 3 months, 
and every 2–3 months thereafter.
The success of these surgical procedures was compared 
using Kaplan-Meier lifetable analysis. Success was defined 
as a 30% reduction of the IOP from the preoperative IOP 
and maintenance below 21 mmHg with or without the use 
of antiglaucoma agents. When additional surgery was per-
formed, the IOP control was judged as a failure regardless 
of IOP at the time of the decision.
Survival curves were constructed for the two groups. The 
significance of the differences in success was determined 
using the log rank test. When the IOP was higher than the 
targeted pressure in two consecutive examinations, the bleb 
was considered to have failed. When additional glaucoma 
surgery was performed, the IOP control was judged as a fail-
ure regardless of the IOP level at the time of the decision.
The significance of the differences in the demographic 
characteristics of the subjects and the incidence of surgical 
complications were determined using Mann-Whitney U tests 
and Fisher’s Exact probability tests. The IOP changes were 
evaluated using Mann-Whitney tests and Wilcoxon signed-
rank tests. A P value of ,0.05 was considered statistically 
significant.
Results
The demographic data of the patients are summarized in 
Tables 1 and 2. There were no significant differences in age, 
duration of follow-up, preoperative IOP, number of prior sur-
geries, number of prescribed antiglaucoma medications, and 
type of glaucoma between the nonamnion amnion groups.
The pretrabeculectomy (former trabeculectomy before 
revision) IOPs were 21.2 ± 4.0 mmHg in the nonamnion 
group and 21.8 ± 3.8 mmHg in the amnion group.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Table 1 Patient demographics
Amniotic membrane
- +
(n = 24) (n = 12) P value
Age (years)
  Mean ± sD 61.7 ± 13.1 61.4 ± 16.6 0.675*
  range 36–84 38–83
Follow-up period (months)
  Mean ± sD 9.6 ± 4.5 9.6 ± 4.9 0.931*
  range 6–20 6–16
Preoperative iOP (mmhg)
  Mean ± sD 21.4 ± 6.5 21.8 ± 4.6 0.469*
  range 15–48 16–30
Prior surgeries
  Cataract 15 9 0.708†
  Vitrectomy 4 6 0.053†
  Filtering    1 15 6 0.499†
  surgery    ,2 9 6
number of eye drops 1.4 ± 0.9 1.5 ± 1.0 0.918*
*Mann-Whitney’s U test; †Fisher’s exact probability test.
Abbreviations: SD, standard deviation; IOP, intraocular pressure.
Table 2 Type of glaucoma
Amniotic membrane
- +
(n = 24) (n = 12) P value
Primary open angle glaucoma 11 7 0.725
exfoliation syndrome 2 0 0.543
glaucoma secondary to uveitis 4 1 0.635
neovascular glaucoma 5 4 0.416
Others 2 0 0.543
100
75
50
25
0
05 10 15 20 25
Amnion +
Amnion −
P = 0.109
Follow-up period (months)
S
u
r
v
i
v
a
l
 
r
a
t
e
 
(
%
)
Figure 1 Kaplan-Meier survival curves of the amnion and nonamnion transplant 
groups.  A  plot  of  the  cumulative  probabilities  against  time  that  the  intraocular 
pressure was 30% lower than at baseline.
The mean prebleb revision IOP was 21.4 ± 6.5 mmHg in 
the nonamnion group and 21.8 ± 4.6 mmHg in the amnion 
group. The postoperative IOP at the last visit in the nonam-
nion group was 12.1 ± 5.5 mmHg and that in the amnion 
group was 16.0 ± 3.7 mmHg. In each group, the IOP was 
reduced significantly, although the IOP in the nonamniotic 
group was significantly lower than that in the amniotic group 
(P = 0.025). The number of postoperative antiglaucoma 
eye drops was 0.24 ± 0.60 in the nonamnion group and 
0.58 ± 0.79 in the amnion group (P = 0.105).
In the amnion group, Kaplan-Meier lifetable analysis 
showed that the success rate was 58.3% after six months 
and 21.9% after one year. The success rate in the nonamnion 
group was 74.8% from six months to one year after surgery. 
This difference in the surgical outcome was not significant 
(P = 0.109, see Figure 1).
At the final visit, five eyes had survived in the amnion 
group according to our criterion for success. Two had a fornix-
based conjunctival flap, and three had a limbus-based flap.
The postoperative complications are listed in Table 3. 
Two cases of hyphema were seen in the nonamnion group 
and one in the amnion group. Leakage at the wound edge 
developed in one case in the nonamnion group and three 
cases in the amnion group. Conjunctival sutures were used 
to repair the wound leakage. Hyphema, shallow anterior 
chamber, and choroidal detachment resolved without any 
intervention.
Late complications of trabeculectomy such as hypotonic 
maculopathy, late bleb leak, bleb-associated infection, 
and corneal decompensation were not found in any of our 
patients.
Although appearance of the bleb is an important factor 
that predicts IOP results and bleb-related complications, 
we did not evaluate bleb appearance in this study. All of 
the subjects had had ocular surgery several times and had 
cicatricial conjunctiva.
Discussion
Kaplan-Meier lifetable analyses showed that the success 
rate in the nonamniotic group was 74.8% from six months 
to one year after the surgery. The mean IOP was reduced 
significantly from 21.4 ± 6.5 mmHg to 12.1 ± 5.5 mmHg in 
the nonamnion group (P , 0.001). These findings are in good 
agreement with those of Hara and Shirato13 who reported 
that an IOP under 21 mmHg was achieved in 53.4% without 
medication and in 60.2% with and without medication at 
60 months following conventional bleb revision surgery. 
Anand and Arora14 reported that the probability of main-
taining an IOP between 5 and 18 mmHg or a 20% decrease 
from the preoperative IOP was 64% at three years after Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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These results suggest that a subconjunctival placement of 
amniotic membrane does not improve the filtration in high-
risk eyes. These poorer results using amniotic membranes for 
bleb revision discouraged us from recruiting new patients. 
So the number of the amnion group is smaller than the 
  nonamnion group.
In the amnion group, six cases (50%) were fornix-based, 
and all of the cases in the nonamnion group were limbus-
based because a fornix-based conjunctival flap allowed us to 
fix the amniotic membrane at the edge easier than a limbus-
based flap. Earlier studies15,16 reported that a fornix-based 
conjunctival flap and a limbus-based flap did not significantly 
alter the IOP-lowering effect of trabeculectomy. In our small 
amnion group, the success rates in the limbus-based group 
and fornix-based group were not significantly different. The 
IOP control results seemed to be unrelated to the surgical 
technique of handling the conjunctiva.
There are others who are more uncertain about the use-
fulness of amniotic membranes. Budenz et al17 stated that 
amniotic membrane transplantation did not offer an effective 
alternative to conjunctival advancement for repair of a leak-
ing filtering bleb. The postoperative IOP in their amniotic 
membrane transplantation group was relatively higher than in 
the conjunctival advancement group, although the difference 
was not statistically significant. Demir et al18 concluded that 
amniotic membrane transplantation can depress wound heal-
ing in a rabbit model of glaucoma. However, the amniotic 
membrane was less effective than MMC.
Li et al19 described the usefulness of amniotic membrane 
transplantation for the repair of conjunctival buttonholes dur-
ing trabeculectomy with MMC. They also discussed better 
ways to use amniotic membrane use during glaucoma surgery. 
They concluded that amniotic membrane transplantation 
was useful when used as a platform for re-epithelialization 
as opposed to tissue replacement for conjunctiva after bleb 
  excision. They reported on the importance of the way the 
amniotic membrane was handled to obtain good surgical 
results. Recently, Sheha et al7 reported that amniotic transplan-
tation in trabeculectomy with MMC for refractory glaucoma 
had achieved better IOP reduction than trabeculectomy with 
MMC alone. Although we sutured the amniotic membrane 
over the scleral flap, they placed a single layer of amniotic 
membrane under and around the scleral flap. All of these 
findings indicate that improvements in the surgical procedures 
for handling and placing the amniotic membrane are needed. 
For example, if the amniotic membrane is placed beneath the 
scleral flap, our outcome might have been improved.
Table 3 Postoperative complications
Amniotic membrane
- +
(n = 24) (n = 12) P value
shallow anterior chamber 1 0  0.999
Choroidal detachment 1 0  0.999
hyphema 2 1  0.999
Wound leakage 1 3 0.098
conventional revision surgery. Earlier studies reported that 
the success rate of bleb revision was around 60% although 
there were some differences in the criteria for success. Thus, 
our results in the nonamnion group are in good agreement 
with these earlier findings.
While bleb revision with adjunctive MMC is an effective 
treatment in cases of bleb failure, glaucoma surgeons have 
been recently examining the effectiveness of amnion mem-
brane transplantation. The amniotic membrane is made of 
strong and stable collagen, and has good anti-inflammatory, 
antifibrotic, and antiangiogenic properties. In glaucoma 
filtration surgery, the healing response is characterized by 
fibroblast outgrowth, and the fibrosis has been reported to 
be delayed more by an amniotic membrane than with con-
ventional conjunctival closure.5
For amniotic membrane transplantation, Fujishima et al4 
transplanted the amniotic membrane under a scleral flap and 
sutured it to the sclera. For the 14 eyes of the 13 patients 
with treatment-resistant glaucoma, the IOP was reduced 
to ,20 mmHg after surgery in 13 eyes. Drolsum et al6 used 
a large amniotic membrane, and sutured it to the scleral 
surface, and one end was positioned under the scleral flap 
and the other end was secured to subconjunctival tissue. 
The mean preoperative IOP was 32.2 mmHg, and the mean 
postoperative IOP was 16.4 mmHg. Although there were 
differences in the methods and definition of success, they 
reported that amniotic membrane transplantation was good 
for the revision of failed glaucoma filtering blebs.4–6
These reports encouraged us to try to use the amniotic 
membrane for bleb revision. One year after starting the use of 
amniotic membranes, we evaluated the efficacy of amniotic 
membrane transplantation to repair failed filtration blebs, 
and compared that with conventional bleb revision. Kaplan-
Meier lifetable analyses showed that bleb revision with 
amniotic membrane transplantation was not better than 
conventional bleb revision with MMC in our cases. In fact, 
the postoperative IOP was significantly higher in the amnion-
transplanted group than in the nonamnion-transplanted group. Clinical Ophthalmology
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Amniotic membranes have antifibrotic effects. However, 
the antifibrotic effects are not as potent as that of MMC.18 
The ability of amniotic membrane transplantation to sup-
press the fibroblast proliferation of the conjunctiva in eyes 
with refractory glaucoma may not be strong enough to 
maintain a functional bleb. This can be another reason for 
the mixed results of amniotic membrane transplantation in 
glaucoma-filtering surgery. To use the amniotic membrane 
for bleb revision before the bleb becomes severely scarred 
may be one of the methods that might improve the surgical 
results.
There were no severe complications such as hypotonic 
maculopathy, late bleb leaks, and bleb-associated infection in 
our cases. Other reports of amniotic membrane transplanta-
tion have also reported no damaging complications.9–11
Conclusion
The revision of a failed filtering bleb with adjunctive MMC 
is an effective way of lowering IOP. The use of amniotic 
membrane transplantation did not enhance the surgical 
outcome in our cases. Establishing better ways to handle 
amniotic membrane may also be a key factor in improving 
surgical results.
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